Metraipolis › archive › dc_016b5315bb26

Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer — Europe PMC PMID:41122972

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41122972
DOI
10.1172/jci.insight.196230
License (as archived)
solo-consultazione
Archived
2026-11-09T03:52:59.504Z
SHA-256 of the archived text
07b884d3e93fac74458be99dd6afb92c7fabc44de747cd6e0344bdbc573510a8
Stable URL of this page
https://metraipolis.com/documento/dc_016b5315bb26

How to cite

Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer — Europe PMC PMID:41122972 — Europe PMC (en), https://europepmc.org/article/MED/41122972 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_016b5315bb26 (Metraipolis archive dc_016b5315bb26, sha256 07b884d3e93fac74458be99dd6afb92c7fabc44de747cd6e0344bdbc573510a8)
BibTeX
@misc{dc016b5315bb26,
  title = {Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer — Europe PMC PMID:41122972},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41122972},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_016b5315bb26; sha256 07b884d3e93fac74458be99dd6afb92c7fabc44de747cd6e0344bdbc573510a8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41122972. Agents can read the archived copy with the MCP tool read_document.